Ceruloplasmin and iron in Alzheimer's disease and Parkinson's disease: A synopsis of recent studies

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 515-521

  Kristinsson, Jakob ^a   Snaedal, Jón ^b   Tórsdóttir, Gudlaug ^a,b   Jóhannesson, Torkell ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

Alzheimer's disease; Ceruloplasmin; Copper; Iron; Parkinson's disease

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CERULOPLASMIN; IRON; TAU PROTEIN;

ALZHEIMER DISEASE; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; MOLECULAR PATHOLOGY; NEUROFIBRILLARY TANGLE; NONHUMAN; PARKINSON DISEASE; REVIEW; SENILE PLAQUE;

EID: 84869234409     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S34729     Document Type: Review

References (53)

1. Roeser H P, Lee GR, Nacht S, Cartwright GE. The role of ceruloplasmin in iron metabolism. J Clin Invest. 1970;49:2408-2417.
2. Harris ZL, Durley A P, Man TK, Gitlin JD. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron effux. Proc Natl Acad Sci. 1999;96:10812-10817.
3. Jeong SY, David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron effux from cells in the central nervous system. J Biol Chem. 2003;278:27144-27148.
4. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT, Gitlin JD. Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci. 1995;92:2539-2543.
5. Harris ZL, Klomp LW, Gitlin JD. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr. 1998;67(Suppl):972S-977S.
6. Connor JR, Menzies SL, St Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res. 1992;31:75-83.
7. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. Proc Natl Acad Sci. 1997;94:9866-9868.
8. Ponka P. Hereditary causes of disturbed iron homeostasis in the central nervous system. Ann N Y Acad Sci. 2004;1012:267-281.
9. Jin L, Wang J, Zhao L, et al. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain. 2011;134:50-58.
10. Martinez-Hernandez R, Montes S, Higuera-Calleja J, et al. Plasma ceruloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: A pilot study. Neurochem Res. 2011;36:2111-2115.
11. Harris ZL, Morita H, Gitlin JD. The biology of human ceruloplasmin. In: Messerschmidt A, editor. Multi-Copper Oxidases. Singapore: World Scientifc; 1997:285-305.
12. Torsdottir G, Gudmundsson G, Kristinsson J, Snaedal J, Johannesson T. Ceruloplasmin and superoxide dismutase (SOD1) in heterozygotes for Wilson's disease: A case control study. Neuropsychiatr Dis Treat. 2009;5:55-59.
13. Torsdottir G, Kristinsson J, Sveinbjörnsdottir S, Snaedal J, Johannesson T. Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacol Toxicol. 1999;85:239-243.
14. Torsdottir G, Sveinbjörnsdottir S, Kristinsson J, Snaedal J, Johannesson T. Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: A follow-up study. J Neurol Sci. 2006;241:53-58.
15. Snaedal J, Kristinsson J, Gunnarsdottir S, Olafsdottir A, Baldvinsson M, Johannesson T. Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease. A case-control study. Dement Geriatr Cogn Disord. 1998;9:239-242.
16. Torsdottir G, Kristinsson J, Snaedal J, Johannesson T. Ceruloplasmin and iron proteins in the serum of patients with Alzheimer's disease. Dement Geriatr Cogn Disord Extra. 2011;1:366-371.
17. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci. 2004;5: 863-873.
18. Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimer's Dis. 2009;16:879-895.
19. Barnham KJ, Masters CL, Torsdottir G, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov. 2004;3:205-214.
20. Johannesson T, Kristinsson J, Torsdottir G, Snaedal J. Serúlóplasmín og járn. Tengsl vi{eth} Alzheimersjúkdóm og Parkinsonsjúkdóm. [Ceruloplasmin (Cp) and iron in connection with Parkinson's disease (PD) and Alzheimer's disease (AD)]. Laeknabladid. 2012;98:531-537. Icelandic (with English summary).
21. Torsdottir G, Kristinsson J, Hreidarsson S, Snaedal J, Johannesson T. Copper, ceruloplasmin and superoxide dismutase (SOD1) in patients with Down's syndrome. Pharmacol Toxicol. 2001;89:320-325.
22. Torsdottir G, Kristinsson J, Snaedal J, et al. Case-control studies on ceruloplasmin and superoxide dismutase (SOD1) in neurodegenerative diseases: A short review. J Neurol Sci. 2010;299:51-54.
23. Arnal N, Cristalli DO, de Alaniz MJT, Marra CA. Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their frst-degree relatives. Brain Res. 2010;1319:118-130.
24. Berg D, Hochstrasser H, Schweitzer KJ, Riess O. Disturbance of iron metabolism in Parkinson's disease - ultrasonography as a biomarker. Neurotox Res. 2006;9:1-13.
25. Hochstrasser H, Bauer P, Walter U, et al. Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson's disease. Neurolog y. 2004;63:1912-1917.
26. Vassiliev V, Harris ZL, Zatta P. Ceruloplasmin in neurodegenerative diseases. Brain Res Rev. 2005;49:633-640.
27. Zecca L, Casella L, Albertini A, et al. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J Neurochem. 2008;106: 1866-1875.
28. Uversky VN. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res. 2004;318:225-241.
29. Inden M, Kitamura Y, Abe M, Tamaki A, Takata K, Taniguchi T. Parkinsonian rotenone mouse model: Reevaluation of long-term administration of rotenone in C57BL/6 mice. Biol Pharm Bull. 2011;34: 92-96.
30. Hineno A, Kaneko K, Yoshida K, Ikeda S. Ceruloplasmin protects against rotenone-induced oxidative stress and neurotoxicity. Neurochem Res. 2011;36:2127-2135.
31. Blennow K. Alzheimers sjukdom - patofysiologi [Alzheimer's disease, pathophysiology]. Information från Läkemedelsverket. 2002;7/8:21-34. Swedish.
32. Yuraszeck TM, Neveu P, Rodriguez-Fernandez M, Robinson A, Kosik KS, Doyle III FJ. Vulnerabilities in the tau network and the role of ultrasensitive points in tau pathophysiology. PLoS Comput Biol. 2010; 6(11):e1000997.
33. Texel SJ, Xu X, Harris ZL. Ceruloplasmin in neurodegenerative diseases. Biochem Soc Trans. 2008;36:1277-1281.
34. Connor JR, Menzies SL. Cellular management of iron in the brain. J Neurol Sci. 1995;134(Suppl):33-44.
35. Gaggelli E, Kozlowski H, Valensin D, Valensin G. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem Rev. 2006;106: 1995-2044.
36. Smith MA, Zhu X, Tabaton M, et al. Increased iron and free radical generation in preclinical Alzheimer's disease and mild cognitive impairment. J Alzheimers Dis. 2010;19:363-372.
37. Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer's disease. J Neuropathol Exp Neurol. 2001;60: 759-767.
38. Schrag M, Mueller C, Oyoyo U, Smith MA, Kirsch WM. Iron, zinc and copper in the Alzheimer's disease brain: A quantitative meta-analysis. Some insight on the infuence of citation bias on scientifc opinion. Prog Neurobiol. 2011;94:296-306.
39. Quintana C, Bellefqih S, Laval JY, et al. Study of the localization of iron, ferritin, and hemosiderin in Alzheimer's disease hippocampus by analytical microscopy at the subcellular level. J Struct Biol. 2006;153: 42-54.
40. Patel BN, Dunn RJ, Jeong SY, Zhu Q, Julien J P, David S. Ceruloplasmin regulates iron levels in the CSN and prevents free radical injury. J Neurosci. 2002;22(15):6578-6586.
41. Brewer GJ, Kanzer SH, Zimmerman EA, Celmins DF, Heckman SM, Dick R. Copper and ceruloplasmin abnormalities in Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2010;25:490-497.
42. Sparks DL, Schreurs BG. Trace amounts of copper in water induce beta-amyoid plaques and learning deficits in a rabbit model of Alzheimer ́s disease. Proc Natl Acad Sci. 2003;100:11065-11069.
43. Squitti R, Pasqualetti P, Dal Forno G, et al. Excess of serum copper not related to ceruloplasmin in Alzheimer's disease. Neurology. 2005; 64:1040-1046.
44. Squitti R, Bressi F, Pasqualetti P, et al. Longitudinal prognostic value of serum "free" copper in patients with Alzheimer's disease. Neurology. 2009;72:50-55.
45. Squitti R, Ghidoni R, Scrascia F, et al. Free copper distinguishes mild cognitive impairment subjects from healthy elderly individuals. J Alzheimers Dis. 2011;23:239-248.
46. Hoogenraad TU. Paradigm shift in treatment of Alzheimer's disease: zinc therapy now a conscientious choice for care of individual patients. Int J Alzheimers Dis. 2011:Article ID 492686.
47. Capo CR, Arciello M, Squitti R, et al. Features of ceruloplasmin in the cerebrospinal fuid of Alzheimer's disease patients. Biometals. 2008; 21:367-372.
48. Choi BS, Zheng W. Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Res. 2009;1248:14-21.
49. Bucossi S, Ventriglia M, Panetta V, et al. Copper in Alzheimer's disease: A meta-analysis of serum, plasma, and cerebrospinal fuid studies. J Alzheimers Dis. 2011;24:175-185.
50. Sveinbjörnsdottir S, Hicks AA, Jonsson T, et al. Familial aggregation of Parkinson's disease in Iceland. N Engl J Med. 2000;343:1765-1770.
51. Palsson PA, Grimsson H. Demyelination in lambs from ewes which feed on seaweeds. Proc Soc Exper Biol Med. 1953;83:518-520.
52. Palsson PA, Grimsson H. Fjöruskjögur. Copper defciency in lambs. Búna{eth}arrit. 1954;66:32-50. Icelandic.
53. Hollingworth P, Harold D, Sims R, et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet. 2011;43:429-436.